Clinic Receives Media Award
The Cancer Preventorium, a Washington, D.C., clinic offering preventive cancer screenings for Latino immigrants, was 1 of 11 winners of the Innovation in Prevention Awards from the U.S. Department of Health and Human Services for its media program. The awards are presented to organizations for promoting healthy lifestyles. Dr. Elmer Huerta (at right), who founded the clinic at the Washington Cancer Institute on the campus of the Washington Hospital Center in 1994, accepted the award on behalf of the Cancer Preventorium. The clinic uses radio and television to encourage Latinos in the area to visit a physician as a preventive measure, before they develop disease symptoms. Dr. Huerta is a former member of the National Cancer Advisory Board and maintains a close relationship with NCI. He also produces and hosts three health-related radio shows, one of which is nationally syndicated. He started a weekly TV program, Hablemos de Salud (Let's Talk About Health), in 1996 on MHz NETWORKS, a Washington-area station with multicultural programming.
Comments Invited on Future Biospecimen Needs
Last Chance for Web Site Input on Future of Clinical Trials
Imaging Informatics Resource Launched Through Public-Private Partnership
IDRI's goal is to rapidly create a Web-accessible and validated CT imaging database to support the development, optimization, and testing of application-specific software tools with a goal of improving the clinical management of lung cancer. The IDRI demonstration project is an expansion of NCI's Lung Imaging Database Consortium and the Lung Cancer Screening Trial. Imaging companies participating in the initiative include AGFA, Fujifilm, GE Healthcare, iCAD, Kodak Health Imaging, Siemens Medical Solutions, Philips Medical Systems, and R2 Technology.
IDRI is part of NCI's efforts to speed the development and dissemination of quantitative informatics tools for imaging and integration of other patient data for clinical decision making. This will help enable the use of molecular imaging and other molecular-based methods for patient-specific diagnosis and assessment of therapy response.
For additional information on this initiative, contact Dr. Larry Clarke at firstname.lastname@example.org. Corporations interested in joining this partnership should contact Julie Wolf-Rodda of FNIH at email@example.com.
Coffey Discusses Common Denominators of Cancer